ESR1 and breast cancer: In a Danish observational study, a cohort of postmenopausal women with early-stage invasive estrogen receptor-positive nonmetastatic BC who received no treatment or 5 years of adjuvant endocrine therapy were followed over time to evaluate the recurrence and mortality that each had and according to VET, MHT, or no therapy received.